Literature DB >> 2386616

Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy.

E Pedrol1, J M González-Clemente, J M Gatell, J Mallolas, J M Miró, F Graus, R Alvarez, J M Mercader, J Berenguer, M T Jiménez de Anta.   

Abstract

Fifty-five episodes of central nervous system (CNS) toxoplasmosis developing in 43 of the 329 AIDS cases seen at our institution were diagnosed during a 34-month period and were prospectively studied. Acute episodes were treated with a pyrimethamine/sulfadiazine (P/S) combination for a mean of 21 days. Because of a previously known major allergy to sulfonamides, three episodes were treated with clindamycin instead of sulphadiazine. In those patients who accepted maintenance therapy, a combination of P/S or pyrimethamine and clindamycin (P/C) was administered 2 days per week. Thirty-six patients (83.7%) survived the first episode. Four of these 36 were lost to further study. Six of the 12 (50%) who decided not to undergo maintenance therapy relapsed (mean follow-up: 12 months). Fourteen patients were given P/S and none relapsed while they were on maintenance therapy (mean follow-up: 10.3 months). Six patients received an intermittent maintenance treatment with P/C and one relapsed 2 months after starting the maintenance therapy (mean follow-up: 13.7 months). We conclude that an intermittent (2 days per week) maintenance treatment for CNS toxoplasmosis with P/S was effective in preventing relapses, although prospective randomized studies remain to be done.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386616     DOI: 10.1097/00002030-199006000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans.

Authors:  M B Purner; R L Berens; P B Nash; A van Linden; E Ross; C Kruse; E C Krug; T J Curiel
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

Review 5.  Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions?

Authors:  G E Harb; M A Jacobson
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

6.  Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.

Authors:  D Torre; S Casari; F Speranza; A Donisi; G Gregis; A Poggio; S Ranieri; A Orani; G Angarano; F Chiodo; G Fiori; G Carosi
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 7.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

8.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

9.  Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.

Authors:  B Ruf; D Schürmann; F Bergmann; W Schüler-Maué; T Grünewald; H J Gottschalk; H Witt; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

10.  Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.

Authors:  J P Chave; A Munafo; J Y Chatton; P Dayer; M P Glauser; J Biollaz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.